Recent studies have demonstrated that PP2A phosphatase activity is markedly reduced in both CD34+ CML and CD34+/CD19+ Ph+ B-ALL bone marrow progenitors [5, 6]. This evidence concerns the gene PTPA and chronic myelogenous leukemia, BCR-ABL1 positive.